Burosumab, a human immunoglobulin G1 monoclonal antibody that targets fibroblast growth factor 23 (FGF23), was developed to treat X-linked hypophosphatemic rickets/osteomalacia (XLH). Here, FGF23 is linked to X-linked hypophosphatemia.